Iron Sucrose is an intravenously administered iron product indicated in the treatment of iron deficiency anemia. It is frequently used in patients undergoing hemodialysis, those undergoing erythropoietin therapy, and/or patients who have chronic kidney disease. It is a type 2 complex which limits the maximum dose that can be given to 200mg which requires several administrations.
Iron sucrose Injectable is a sterile aqueous complex, non-phylogenic aqueous complex containing 20 mg/mL of Iron suitable for intravenous administration.
Iron sucrose is dissociated into iron and sucrose by the reticuloendothelial system and iron is transferred from the blood to a bone marrow. The Ferritin the iron storage protein binds and sequesters iron into a nontoxic iron that is easily available. The iron binds to plasma transferring that is carries iron to extracellular fluid to supply to tissues. The transferring receptors presented in membrane binds transferrin iron complex which is then internalized in vesicles iron is released within the cell and transferrin-receptor complex is return to the cell membrane transferrin without iron is then releases to the plasma. The intracellular iron becomes hemoglobin on circulating red blood cells. Transferrin synthesis increased Ferritin production reduced in iron deficiency.